Drug Profile
PDA 002
Alternative Names: PDA-002; PDAC cells; Placental-derived adherent cells intramuscularLatest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Developer Celgene Corporation; Celularity
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Facioscapulohumeral muscular dystrophy
- Discontinued Diabetic foot ulcer; Diabetic neuropathies; Peripheral arterial disorders
Most Recent Events
- 20 Mar 2024 Celularity submits Orphan Drug designation application to US FDA for Facioscapulohumeral Muscular Dystrophy
- 20 Mar 2024 US FDA approves IND application for PDA 002 in Facioscapulohumeral Muscular Dystrophy
- 20 Mar 2024 Celularity plans a phase I/II trial for Facioscapulohumeral Muscular Dystrophy in the second half of 2024